Search

Your search keyword '"Ferrari, Jacqueline"' showing total 17 results
Start Over Author "Ferrari, Jacqueline"
17 results on '"Ferrari, Jacqueline"'

1. Risk Prediction for Clonal Cytopenia: Multicenter Real-World Evidence.

Author

Xie, Zhuoer, Komrokji, Rami S, Al-Ali, Najla, Regelson, Alexandra, Geyer, Susan, Patel, Anand A, Saygin, Caner, Zeidan, Amer M, Bewersdorf, Jan Philipp, Mendez, Lourdes M, Kishtagari, Ashwin, Zeidner, Joshua F, Coombs, Catherine C, Madanat, Yazan F, Chung, Stephen S, Badar, Talha, Foran, James M, Desai, Pinkal, Tsai, Charlton, Griffiths, Elizabeth A, Al Malki, Monzr M, Amanam, Idoroenyi, Lai, Catherine, Deeg, H Joachim, Ades, Lionel, Arana-Yi, Cecilia, Osman, Afaf Eg, Dinner, Shira Naomi, Abaza, Yasmin, Taylor, Justin, Chandhok, Namrata S, Soong, Deborah, Brunner, Andrew M, Carraway, Hetty E, Singh, Abhay, Elena, Chiara, Ferrari, Jacqueline, Galli, Anna, Pozzi, Sara, Padron, Eric, Patnaik, Mrinal M, Malcovati, Luca, Savona, Michael R, and Al-Kali, Aref

Subjects
Cardiorespiratory Medicine and Haematology, Clinical Sciences, Paediatrics and Reproductive Medicine, Immunology, Biochemistry and cell biology, Cardiovascular medicine and haematology, Paediatrics
Abstract

Clonal cytopenia of undetermined significance (CCUS) represents a distinct disease entity characterized by myeloid-related somatic mutations with a variant allele fraction of ≥2% in individuals with unexplained cytopenia(s) but without a myeloid neoplasm (MN). Notably, CCUS carries a risk of progressing to MN, particularly in cases featuring high-risk mutations. Understanding CCUS requires dedicated studies to elucidate its risk factors and natural history. Our analysis of 357 CCUS patients investigated the interplay between clonality, cytopenia, and prognosis. Multivariate analysis identified 3 key adverse prognostic factors: the presence of splicing mutation(s) (score = 2 points), platelet count

Published
2024

3. Disease correlates and clinical relevance of hereditary α-tryptasemia in patients with systemic mastocytosis

Author

Sordi, Benedetta, Vanderwert, Fiorenza, Crupi, Francesca, Gesullo, Francesca, Zanotti, Roberta, Bonadonna, Patrizia, Crosera, Lara, Elena, Chiara, Fiorelli, Nicolas, Ferrari, Jacqueline, Grifoni, Federica, Sciumè, Mariarita, Parente, Roberta, Triggiani, Massimo, Palterer, Boaz, Mecheri, Valentina, Almerigogna, Fabio, Santi, Raffaella, Di Medio, Lisa, Brandi, Maria Luisa, Iorno, Maria Loredana, Ciardetti, Isabella, Bencini, Sara, Annunziato, Francesco, Mannarelli, Carmela, Pieri, Lisa, Guglielmelli, Paola, Mannelli, Francesco, and Vannucchi, Alessandro M.

Published
2023
Full Text
View/download PDF

4. Relationship between clone metrics and clinical outcome in clonal cytopenia

Author

Gallì, Anna, Todisco, Gabriele, Catamo, Eulalia, Sala, Cinzia, Elena, Chiara, Pozzi, Sara, Bono, Elisa, Ferretti, Virginia Valeria, Rizzo, Ettore, Molteni, Elisabetta, Zibellini, Silvia, Sarchi, Martina, Boveri, Emanuela, Ferrari, Jacqueline, Fiorelli, Nicolas, Camaschella, Clara, Gasparini, Paolo, Toniolo, Daniela, Cazzola, Mario, and Malcovati, Luca

Published
2021
Full Text
View/download PDF

5. Early transfusion patterns improve the Molecular International Prognostic Scoring System (IPSS-M) prediction in myelodysplastic syndromes

Author

Creignou, Maria, Bernard, Elsa, Gasparini, Alessandro, Tranberg, Anna, Todisco, Gabriele, Moura, Pedro Luis, Ejerblad, Elisabeth, Nilsson, Lars, Garelius, Hege, Antunovic, Petar, Lorenz, Fryderyk, Rasmussen, Bengt, Walldin, Gunilla, Mortera-Blanco, Teresa, Jansson, Monika, Tobiasson, Magnus, Elena, Chiara, Ferrari, Jacqueline, Galli, Anna, Pozzi, Sara, Malcovati, Luca, Edgren, Gustaf, Crowther, Michael J., Jaedersten, Martin, Papaemmanuil, Elli, Hellstroem-Lindberg, Eva, Creignou, Maria, Bernard, Elsa, Gasparini, Alessandro, Tranberg, Anna, Todisco, Gabriele, Moura, Pedro Luis, Ejerblad, Elisabeth, Nilsson, Lars, Garelius, Hege, Antunovic, Petar, Lorenz, Fryderyk, Rasmussen, Bengt, Walldin, Gunilla, Mortera-Blanco, Teresa, Jansson, Monika, Tobiasson, Magnus, Elena, Chiara, Ferrari, Jacqueline, Galli, Anna, Pozzi, Sara, Malcovati, Luca, Edgren, Gustaf, Crowther, Michael J., Jaedersten, Martin, Papaemmanuil, Elli, and Hellstroem-Lindberg, Eva

Abstract

Background The Molecular International Prognostic Scoring System (IPSS-M) is the new gold standard for diagnostic outcome prediction in patients with myelodysplastic syndromes (MDS). This study was designed to assess the additive prognostic impact of dynamic transfusion parameters during early follow-up. Methods We retrieved complete transfusion data from 677 adult Swedish MDS patients included in the IPSS-M cohort. Time-dependent erythrocyte transfusion dependency (E-TD) was added to IPSS-M features and analyzed regarding overall survival and leukemic transformation (acute myeloid leukemia). A multistate Markov model was applied to assess the prognostic value of early changes in transfusion patterns. Results Specific clinical and genetic features were predicted for diagnostic and time-dependent transfusion patterns. Importantly, transfusion state both at diagnosis and within the first year strongly predicts outcomes in both lower (LR) and higher-risk (HR) MDSs. In multivariable analysis, 8-month landmark E-TD predicted shorter survival independently of IPSS-M (p < 0.001). A predictive model based on IPSS-M and 8-month landmark E-TD performed significantly better than a model including only IPSS-M. Similar trends were observed in an independent validation cohort (n = 218). Early transfusion patterns impacted both future transfusion requirements and outcomes in a multistate Markov model. Conclusion The transfusion requirement is a robust and available clinical parameter incorporating the effects of first-line management. In MDS, it provides dynamic risk information independently of diagnostic IPSS-M and, in particular, clinical guidance to LR MDS patients eligible for potentially curative therapeutic intervention., Funding Agencies|Edward P. Evans Foundation

Published
2024
Full Text
View/download PDF

6. Assessing the Efficacy of Early Therapies against SARS-CoV-2 in Hematological Patients: A Real-Life Study from a COVID-19 Referral Centre in Northern Italy

Author

Colaneri, Marta, primary, Pieri, Teresa Chiara, additional, Roda, Silvia, additional, Ricciardi, Alessandra, additional, Gotti, Manuel, additional, Ferrari, Jacqueline, additional, Arcaini, Luca, additional, Rattotti, Sara, additional, Piralla, Antonio, additional, Giardina, Federica, additional, Ferrari, Guglielmo, additional, Sacchi, Paolo, additional, Zuccaro, Valentina, additional, Baldanti, Fausto, additional, and Bruno, Raffaele, additional

Published
2022
Full Text
View/download PDF

8. 148. Imipenem-Relebactam activity and genotypic characteristics of Carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa Isolates from Latin American Infections - Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017 – 2020

Author

Mizuno, Gustavo, primary, Polis, Thales, additional, Ferrari, Jacqueline, additional, Pavia, Jacqueline, additional, Beirão, Elisa, additional, Gales, Ana C, additional, Tuon, Felipe, additional, Alcantara, Alexandre, additional, and Batista, Paula M, additional

Published
2022
Full Text
View/download PDF

9. ATIVIDADE DE IMIPENEM-RELEBACTAM E COMPARADORES CONTRA ISOLADOS DE KLEBSIELLA PNEUMONIAE DE INFECÇÕES DO TRATO URINÁRIO EM PACIENTES IDOSOS. DADOS DO STUDY FOR MONITORING ANTIMICROBIAL RESISTANCE TRENDS (SMART) 2017 - 2020

Author

Beirão, Elisa Maria, primary, Ferrari, Jacqueline, additional, Mizuno, Gustavo, additional, Alcântara, Alexandre Augusto, additional, Santiago, Felipe Silva, additional, Polis, Thales Jose, additional, and Santos, Priscila Pereira, additional

Published
2022
Full Text
View/download PDF

10. ATIVIDADE DE CEFTOLOZANE-TAZOBACTAM E COMPARADORES CONTRA PSEUDOMONAS AERUGINOSA COLETADOS DE INFECÇÕES DO TRATO RESPIRATÓRIO NO BRASIL: RESULTADOS DO ESTUDO DE MONITORAMENTO DE TENDÊNCIAS DE RESISTÊNCIA ANTIMICROBIANA (SMART) 2016-2020

Author

Ferrari, Jacqueline Roque, primary, Gales, Ana Cristina, additional, Beirão, Elisa Maria, additional, Tuon, Felipe Francisco, additional, Mizuno, Gustavo, additional, Santiago, Felipe da Silva, additional, Alcantar, Alexandre Augusto Assis, additional, Polis, Thales Jose, additional, Della Negra De, Marina, additional, and Albor, Jacqueline Patricia Paiva, additional

Published
2022
Full Text
View/download PDF

12. A case of pediatric indolent systemic mastocytosis: The role of UVB‐NB phototherapy in the treatment of cutaneous lesions.

Author

Brazzelli, Valeria, Bossi, Grazia, Bonelli, Alice, Isoletta, Eugenio, Volontè, Martina, Barruscotti, Stefania, De Amici, Mara, Bono, Elisa, Ferrari, Jacqueline, and Boveri, Emanuela

Subjects
ITCHING, MAST cell disease, PHOTOTHERAPY, INFORMED consent (Medical law)
Abstract

Narrow-band UVB phototherapy and psoralen-ultraviolet a photochemotherapy in the treatment of cutaneous mastocytosis: a study in 20 patients. 14 Prignano F, Troiano M, Lotti T. Cutaneous mastocytosis: successful treatment with narrowband ultraviolet B phototherapy. A case of pediatric indolent systemic mastocytosis: The role of UVB-NB phototherapy in the treatment of cutaneous lesions. [Extracted from the article]

Published
2023
Full Text
View/download PDF

13. Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV.

Author

Zappasodi, Patrizia, Cattaneo, Chiara, Valeria Ferretti, Virginia, Mina, Roberto, José María Ferreri, Andrés, Merli, Francesco, Oberti, Margherita, Krampera, Mauro, Romano, Alessandra, Zerbi, Caterina, Ferrari, Jacqueline, Cavo, Michele, Salvini, Marco, Bertù, Lorenza, Stefano Fracchiolla, Nicola, Marchesi, Francesco, Massaia, Massimo, Marasco, Vincenzo, Cairoli, Roberto, and Maria Scattolin, Anna

Subjects
HEMATOLOGIC malignancies, COVID-19, ACUTE myeloid leukemia, TREATMENT effectiveness, INFECTION
Abstract

The impact of secondary infections (SI) on COVID‐19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID‐19. Among 1741 HM patients with COVID‐19, 134 (7.7%) had 185 SI, with a 1‐month cumulative incidence of 5%. Median time between COVID‐19 diagnosis and SI was 16 days (IQR: 5–36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID‐19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram‐negative isolates (18.9%), while coagulase‐negative Staphylococci were the most frequent among Gram‐positive (14.2%). The 30‐day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID‐19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

14. Systematic screening for SARS-CoV-2 in patients with hematological malignancies on active anticancer treatment in the outpatient setting

Author

Varettoni, Marzia, primary, Mangiacavalli, Silvia, additional, Rattotti, Sara, additional, Cartia, Claudio Salvatore, additional, Cavalloni, Chiara, additional, Rossetti, Franca, additional, Ferretti, Virginia Valeria, additional, Bergamini, Fabio, additional, Trotti, Chiara, additional, Fiorelli, Nicolas, additional, Pagani, Giuseppina, additional, Zerbi, Caterina, additional, Ferrari, Jacqueline, additional, Cristinelli, Caterina, additional, Muzzi, Alba, additional, Marena, Carlo, additional, Baldanti, Fausto, additional, Bruno, Raffaele, additional, and Arcaini, Luca, additional

Published
2021
Full Text
View/download PDF

16. Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations

Author

Bonifacio, Massimiliano, primary, Elena, Chiara, additional, D'Adda, Mariella, additional, Scaffidi, Luigi, additional, Pucci, Mairi, additional, Aprili, Fiorenza, additional, Ferrari, Jacqueline, additional, Tucci, Alessandra, additional, Stagno, Fabio, additional, Scortechini, Anna Rita, additional, Binotto, Gianni, additional, Annunziata, Mario, additional, Miggiano, Maria Cristina, additional, Capodanno, Isabella, additional, Galimberti, Sara, additional, Tiribelli, Mario, additional, Giugliano, Emilia, additional, Caocci, Giovanni, additional, Crugnola, Monica, additional, Ronchi, Paola, additional, Russo, Sabina, additional, Tinelli, Martina, additional, Tafuri, Agostino, additional, Bocchia, Monica, additional, Malato, Alessandra, additional, Krampera, Mauro, additional, Lippi, Giuseppe, additional, Breccia, Massimo, additional, Saglio, Giuseppe, additional, and Gozzini, Antonella, additional

Published
2020
Full Text
View/download PDF

17. Secondary infections worsen the outcome of COVID-19 in patients with hematological malignancies: A report from the ITA-HEMA-COV

Author

Zappasodi P, Cattaneo C, Ferretti V, Mina R, Ferreri AJ, Merli F, Oberti M, Krampera M, Romano A, Zerbi C, Ferrari J, Cavo M, Marco Salvini M, Bertù L, Fracchiolla N, Marchesi F, Massaia M, Marasco V, Cairoli R, Scattolin AM, Vannucchi AM, Gambacorti-Passerini C, Musto P, Gherlinzoni F, Cuneo A, Pinto A, Trentin L, Bocchia M, Galimberti, Coviello E, Morotti A, Falini B, Turrin M, Tafuri A, Billio A, Gentile M, Lemoli M, Venditti A, Della Porta M, Lanza F, Rigacci L, Tosi P, Mohamed S, Corso A, Luppi M, Giuliani N, Busca A, Pagano L, Bruno R, Grossi P, Corradini P, Passamonti F, Arcaini L., Zappasodi, P, Cattaneo, C, Ferretti, V, Mina, R, Ferreri, A, Merli, F, Oberti, M, Krampera, M, Romano, A, Zerbi, C, Ferrari, J, Cavo, M, Marco Salvini, M, Bertù, L, Fracchiolla, N, Marchesi, F, Massaia, M, Marasco, V, Cairoli, R, Scattolin, A, Vannucchi, A, Gambacorti-Passerini, C, Musto, P, Gherlinzoni, F, Cuneo, A, Pinto, A, Trentin, L, Bocchia, M, Galimberti, Coviello, E, Mc, Morotti, A, Falini, B, Turrin, M, Tafuri, A, Billio, A, Gentile, M, Lemoli, M, Venditti, A, Della Porta, M, Lanza, F, Rigacci, L, Tosi, P, Mohamed, S, Corso, A, Luppi, M, Giuliani, N, Busca, A, Pagano, L, Bruno, R, Grossi, P, Corradini, P, Passamonti, F, Arcaini, L, Zappasodi, Patrizia, Cattaneo, Chiara, Ferretti, Virginia Valeria, Mina, Roberto, Ferreri, Andrés José María, Merli, Francesco, Oberti, Margherita, Krampera, Mauro, Romano, Alessandra, Zerbi, Caterina, Ferrari, Jacqueline, Cavo, Michele, Salvini, Marco, Bertù, Lorenza, Fracchiolla, Nicola Stefano, Marchesi, Francesco, Massaia, Massimo, Marasco, Vincenzo, Cairoli, Roberto, Scattolin, Anna Maria, Vannucchi, Alessandro Maria, Gambacorti-Passerini, Carlo, Musto, Pellegrino, Gherlinzoni, Filippo, Cuneo, Antonio, Pinto, Antonello, Trentin, Livio, Bocchia, Monica, Galimberti, Sara, Coviello, Elisa, Tisi, Maria Chiara, Morotti, Alessandro, Falini, Brunangelo, Turrini, Mauro, Tafuri, Agostino, Billio, Atto, Gentile, Massimo, Lemoli, Roberto Massimo, Venditti, Adriano, Della Porta, Matteo Giovanni, Lanza, Francesco, Rigacci, Luigi, Tosi, Patrizia, Mohamed, Sara, Corso, Alessandro, Luppi, Mario, Giuliani, Nicola, Busca, Alessandro, Pagano, Livio, Bruno, Raffaele, Grossi, Paolo Antonio, Corradini, Paolo, Passamonti, Francesco, and Arcaini, Luca

Subjects
Cancer Research, Lymphoma, Coinfection, COVID-19, Hematology, General Medicine, Settore MED/15, hematological malignancie, secondary infections, Settore MED/15 - MALATTIE DEL SANGUE, COVID-19 Testing, Oncology, Hematologic Neoplasms, secondary infection, outcome, Humans, hematological malignancies, Aged
Abstract

The impact of secondary infections (SI) on COVID-19 outcome in patients with hematological malignancies (HM) is scarcely documented. To evaluate incidence, clinical characteristics, and outcome of SI, we analyzed the microbiologically documented SI in a large multicenter cohort of adult HM patients with COVID-19. Among 1741 HM patients with COVID-19, 134 (7.7%) had 185 SI, with a 1-month cumulative incidence of 5%. Median time between COVID-19 diagnosis and SI was 16 days (IQR: 5-36). Acute myeloid leukemia (AML) and lymphoma/plasma cell neoplasms (PCN) were more frequent diagnoses in SI patients compared to patients without SI (AML: 14.9% vs. 7.1%; lymphoma/PCN 71.7% vs. 65.3%). Patients with SI were older (median age 70 vs. 66 years, p = 0.002), with more comorbidities (median Charlson Comorbidity Index 5 vs. 4, p < 0.001), higher frequency of critical COVID-19 (19.5% vs. 11.5%, p = 0.046), and more frequently not in complete remission (75% vs. 64.7% p = 0.024). Blood and bronchoalveolar lavage were the main sites of isolation for SI. Etiology of infections was bacterial in 80% (n = 148) of cases, mycotic in 9.7% (n = 18) and viral in 10.3% (n = 19); polymicrobial infections were observed in 24 patients (18%). Escherichia coli represented most of Gram-negative isolates (18.9%), while coagulase-negative Staphylococci were the most frequent among Gram-positive (14.2%). The 30-day mortality of patients with SI was higher when compared to patients without SI (69% vs. 15%, p < 0.001). The occurrence of SI worsened COVID-19 outcome in HM patients. Timely diagnosis and adequate management should be considered to improve their prognosis.

Published
2022

Catalog

Books, media, physical & digital resources
See catalog results